Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Azelaic-acid | hsa00480 | Glutathione metabolism | 3.29E-04 | 4 | Q9UJ14, Q16772, P09211, P30041 | GGTL3, GSTA3, GSTP1, PRDX6 | More | | Azelaic-acid | hsa00620 | Pyruvate metabolism | 3.19E-02 | 2 | P40926, P14550 | MDH2, AKR1A1 | More | | Azelaic-acid | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.46E-03 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | | Azelaic-acid | hsa00982 | Drug metabolism - cytochrome P450 | 1.06E-02 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | | Azelaic-acid | hsa00983 | Drug metabolism - other enzymes | 1.72E-02 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | | Azelaic-acid | hsa01100 | Metabolic pathways | 8.43E-03 | 11 | P35790, Q16772, P09211, Q9UJ14, P30041, P40926, Q7KZN9, P15121, Q9UHK6, Q86VZ5, Q9BQB6 | CHKA, GSTA3, GSTP1, GGTL3, PRDX6, MDH2, COX15, AKR1B1, AMACR, SGMS1, VKORC1 | More | | Azelaic-acid | hsa01524 | Platinum drug resistance | 4.44E-02 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | | Azelaic-acid | hsa04064 | NF-kappa B signaling pathway | 4.09E-03 | 8 | P10415, O00463, Q04759, Q9UDY8, Q16548, Q13315, P24522, P09341 | BCL2, TRAF5, PRKCQ, MALT1, BCL2A1, ATM, GADD45A, CXCL1 | More | | Azelaic-acid | hsa04070 | Phosphatidylinositol signaling system | 1.53E-02 | 2 | Q86XP1, Q96DU7 | DGKH, ITPKC | More | | Azelaic-acid | hsa04071 | Sphingolipid signaling pathway | 1.90E-03 | 7 | P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415 | S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2 | More | | Azelaic-acid | hsa04080 | Neuroactive ligand-receptor interaction | 1.00E-02 | 7 | P08311, Q15722, P21453, Q9H228, O00398, P21730, P07550 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, ADRB2 | More | | Azelaic-acid | hsa04140 | Autophagy - animal | 3.19E-02 | 4 | P22694, Q14643, P10415, Q04759 | PRKACB, ITPR1, BCL2, PRKCQ | More | | Azelaic-acid | hsa04145 | Phagosome | 4.48E-02 | 5 | Q15080, P05164, O60603, P35443, P13765 | NCF4, MPO, TLR2, THBS4, HLA-DOB | More | | Azelaic-acid | hsa04210 | Apoptosis | 3.44E-02 | 7 | Q13315, P10415, O76075, P24522, Q16548, P43234, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ITPR1 | More | | Azelaic-acid | hsa04340 | Hedgehog signaling pathway | 2.62E-03 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | Azelaic-acid | hsa04610 | Complement and coagulation cascades | 3.19E-02 | 1 | P0C0L4 | C4A | More | | Azelaic-acid | hsa04612 | Antigen processing and presentation | 3.22E-03 | 8 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Azelaic-acid | hsa04613 | Neutrophil extracellular trap formation | 5.80E-03 | 13 | O60603, P05164, P08246, Q9UM07, Q6FI13, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Azelaic-acid | hsa04621 | NOD-like receptor signaling pathway | 2.62E-02 | 11 | Q16539, Q14643, P10599, Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P09341, P12838 | MAPK14, ITPR1, TXN, ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CXCL1, DEFA4 | More | | Azelaic-acid | hsa04650 | Natural killer cell mediated cytotoxicity | 2.96E-02 | 6 | O60880, P20963, Q13241, P26718, P26717, P26715 | SH2D1A, CD247, KLRD1, KLRK1, KLRC2, KLRC1 | More | | Azelaic-acid | hsa04657 | IL-17 signaling pathway | 3.91E-02 | 7 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF | More | | Azelaic-acid | hsa04658 | Th1 and Th2 cell differentiation | 5.80E-05 | 8 | Q04759, P20963, P09693, Q16539, Q14765, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, MAPK14, STAT4, GATA3, TBX21, HLA-DOB | More | | Azelaic-acid | hsa04659 | Th17 cell differentiation | 1.90E-02 | 6 | Q04759, P13765, Q9UL17, P23771, P09693, P20963 | PRKCQ, HLA-DOB, TBX21, GATA3, CD3G, CD247 | More | | Azelaic-acid | hsa04660 | T cell receptor signaling pathway | 1.40E-04 | 12 | P01375, Q9UDY8, Q04759, P10747, O95267, Q08881, P20963, P09693, P01732, Q13191, Q16539, P49841 | TNF, MALT1, PRKCQ, CD28, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, MAPK14, GSK3B | More | | Azelaic-acid | hsa04922 | Glucagon signaling pathway | 4.23E-02 | 4 | P22694, P06737, Q12778, Q14643 | PRKACB, PYGL, FOXO1, ITPR1 | More | | Azelaic-acid | hsa04924 | Renin secretion | 1.04E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | Azelaic-acid | hsa04928 | Parathyroid hormone synthesis, secretion and action | 4.23E-02 | 4 | Q14643, P22694, P23771, P10415 | ITPR1, PRKACB, GATA3, BCL2 | More | | Azelaic-acid | hsa05133 | Pertussis | 2.63E-02 | 2 | P10145, P0C0L4 | IL8, C4A | More | | Azelaic-acid | hsa05140 | Leishmaniasis | 1.87E-02 | 7 | P13612, O75015, P13765, O60603, P01375, Q16539, Q15080 | ITGA4, FCGR3B, HLA-DOB, TLR2, TNF, MAPK14, NCF4 | More | | Azelaic-acid | hsa05146 | Amoebiasis | 3.91E-02 | 7 | P09341, P27930, P01375, O60603, P05089, P22694, P08311 | CXCL1, IL1R2, TNF, TLR2, ARG1, PRKACB, CTSG | More | | Azelaic-acid | hsa05202 | Transcriptional misregulation in cancer | 3.09E-03 | 16 | Q12778, Q13315, P14780, P27930, Q15744, Q16548, Q13077, O15550, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P12980, P24522 | FOXO1, ATM, MMP9, IL1R2, CEBPE, BCL2A1, TRAF1, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, LYL1, GADD45A | More | | Azelaic-acid | hsa05203 | Viral carcinogenesis | 4.62E-02 | 3 | Q12933, P42229, Q15283 | TRAF2, STAT5A, RASA2 | More | | Azelaic-acid | hsa05204 | Chemical carcinogenesis | 5.46E-03 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | | Azelaic-acid | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.84E-02 | 5 | P20963, P09693, O60603, P10747, Q04759 | CD247, CD3G, TLR2, CD28, PRKCQ | More | | Azelaic-acid | hsa05310 | Asthma | 2.81E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Azelaic-acid | hsa05321 | Inflammatory bowel disease | 1.22E-05 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Azelaic-acid | hsa05323 | Rheumatoid arthritis | 1.60E-02 | 4 | P13765, P10747, P09341, O60603 | HLA-DOB, CD28, CXCL1, TLR2 | More | | Azelaic-acid | hsa05332 | Graft-versus-host disease | 3.96E-04 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | | |